- In June 2024, Medtronic plc announced the first U.S. patient enrollment in its pivotal trial evaluating the Hugo robotic-assisted surgery (RAS) system for general surgery procedures. The trial aims to support FDA clearance in the U.S., following the successful use of Hugo in international markets. This milestone marks a major step in Medtronic’s strategy to disrupt the surgical robotics space dominated by Intuitive Surgical
- In May 2024, CMR Surgical raised USD 165 million in a funding round to accelerate the global expansion of its Versius surgical robotic system. The capital will support entry into new markets and the development of next-generation digital surgical capabilities. Versius has gained popularity for its modular design and ease of integration in smaller hospitals and ambulatory surgery centers
- In March 2024, Intuitive Surgical received CE Mark approval for the da Vinci 5, its next-generation surgical robotic platform. The system includes enhanced AI-driven features, improved haptic feedback, and greater precision for a wide range of procedures. With over 12 million surgeries performed globally using da Vinci systems, this latest iteration reinforces Intuitive’s leadership in the field
- In January 2024, Johnson & Johnson’s MedTech division unveiled updates on its OTTAVA surgical robot, announcing plans to begin clinical trials in late 2024. Unlike traditional robotic systems, OTTAVA features a compact, table-mounted design integrated with imaging and analytics. Its development represents J&J’s continued effort to compete in the growing autonomous surgical robotics landscape
